Open an account

Quest Diagnostics

DGX · NYSE

$237.12+$2.21 (+0.94%)TodayMarket closed ·
Prev close $234.91

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. The company is headquartered in Secaucus, New Jersey and currently employs 46,000 full-time employees. The firm provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. The company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. The company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The company also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

Employees
46,000
Headquarters
Secaucus, New Jersey
Listed
Dec 17, 1996
Sector
Health Care
Industry
Health Care Providers & Services
Website
questdiagnostics.com

DGX key statistics

Market cap
26.17B
Price-earnings ratio
24.94
Dividend yield
1.39%
Average volume
1.12M
Volume
1.10M
Open price
$236.00
High today
$237.29
Low today
$234.06
52 Week high
$248.84
52 Week low
$171.18

Quest Diagnostics (DGX) at a glance

Quest Diagnostics (DGX) last traded at $237.12, with a market cap of 26.17B, a price-to-earnings ratio of 24.94 and a dividend yield of 1.39%.

Today the stock has traded between $234.06 and $237.29. The current price is 1.3% above the day's low and 0.1% below its high.

Volume so far is 1.10M shares, in line with the average of 1.12M shares a day.

Over the past year Quest Diagnostics has ranged from $171.18 to $248.84, and now sits 85% of the way up that range.

Quest Diagnostics met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $3.12 per share against an estimate of $2.85.

The average analyst price target is $250.60, 5.7% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

42%of 12 analyst ratings say Buy
  • Buy41.7%
  • Hold58.3%
  • Sell0.0%
Price target · 18 analystsAvg $250.60
Low
$210.42
Now
$237.12
High
$278.25

DGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 3.5% on average.

  1. Q3 FY24: reported $2.30 per share against an estimate of $2.28
  2. Q4 FY24: reported $2.33 per share against an estimate of $2.21
  3. Q1 FY25: reported $2.21 per share against an estimate of $2.17
  4. Q2 FY25: reported $2.62 per share against an estimate of $2.60
  5. Q3 FY25: reported $2.60 per share against an estimate of $2.53
  6. Q4 FY25: reported $2.42 per share against an estimate of $2.38
  7. Q1 FY26: reported $2.50 per share against an estimate of $2.37
  8. Q2 FY26: reported $3.12 per share against an estimate of $2.85

DGX news

  • Press releasePRNewswire

    Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

  • Press releasePRNewswire

    Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension

  • Press releasePRNewswire

    Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

  • Press releasePRNewswire

    Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

  • Tanya Rawat

    CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027

  • Press releasePRNewswire

    Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics

  • Press releasePRNewswire

    Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

Similar companies

Companies in the same industry as Quest Diagnostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.